Ranchi News Desk

Delveinsight Business Research LLP

The Beta-thalassemia (B-thal) market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market. 

Beta-thalassemia (B-thal): An Overview

Beta-thalassemia (β-thal) is a blood-related disorder and occurs when the body cannot make enough of the protein called hemoglobin (present in red blood cells; RBCs). Due to the lack of hemoglobin in RBCs, they cannot function properly and persist for shorter periods. It occurs due to mutations in the HBB gene on chromosome 11, also inherited in an autosomal, recessive fashion. The severity of the disease depends on the nature of the mutation and the presence of mutations in one or both alleles. Sex-related bias is generally not apparent in β-thal.

The thalassemia spectrum is clinically divided into two main categories based on the patient’s need for blood transfusion—transfusion-dependent thalassemia (TDT) and non-transfusion dependent thalassemia

Beta-thalassemia (B-thal) Market Key Facts

• Endocrine complications and Osteoporosis was found in the majority of patients with Beta-Thalassemia. As per DelveInsight’s estimates, the trend would remain the same during the forecast period.

• The United States accounts for the largest Beta Thalassemia market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain).

• According to the study by Hickman et al., In England approximately, 2,800 (0.44%) carry beta-thalassemia traits annually, and 43 (0.07/1,000) are affected by beta-thalassemia major/intermedia.

Beta-thalassemia (B-thal) Market 

Beta-thalassemia (B-thal) market size shall increase during the forecast period owing to the launch of upcoming therapies

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Beta-thalassemia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Beta-thalassemia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Beta-thalassemia (B-thal) Epidemiology

The epidemiology section covers insights into the historical and current Beta-thalassemia patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Beta-thalassemia (B-thal) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Beta-thalassemia market or expected to get launched in the market during the study period. The analysis covers Beta-thalassemia market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Beta-thalassemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/beta-thalassemia-thal-market

Beta-thalassemia (B-thal) Therapeutics Analysis

In the coming days, the competitive landscape for the Beta-thalassemia (β-thal) market is set to change due to improvements in the diagnosis methodologies, rising awareness of the diseases, and incremental healthcare spending across the world. All of which would expand the market size to enable the drug manufacturers to penetrate more into the market.

Companies across the globe are diligently working toward the development of new treatment therapies for β-thal treatment. Many of the are in the early phase of clinical development and are expected to launch in the coming years. 

Some of the key companies in the Beta-thalassemia (B-thal) Market include:

• Novartis

• Apotex

• Celgene Corporation

• Bluebird Bio

• Protagonist Therapeutics

• Acceleron Pharma

• Agios Pharmaceuticals

• Ionis Pharmaceuticals

• Orchard Therapeutics

• Sangamo Therapeutics

• CRISPR Therapeutics

• DisperSol Technologies

• Kiadis

• Editas Medicine

• La Jolla Pharmaceutical Company

• Vertex Pharmaceuticals

• Sanofi

And many others.

Beta-thalassemia (B-thal) Therapies covered in the report include:

• Desferal

• Exjade

• Ferrirpox (deferiprone)

• ACE-536

• LentiGlobin BB305

• PTG-300

• ACE-011 (Sotatercept)

• Mitapivat

• IONIS TMPRSS6 LRx

• VIT 2763

• Emeramide

• OTL-300

• ST-400

• CTX001

• DST-0509

• ATIR201

• Ruxolitinib

• LJPC-401

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/beta-thalassemia-thal-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Beta-thalassemia (B-thal) Competitive Intelligence Analysis

4. Beta-thalassemia (B-thal) Market Overview at a Glance

5. Beta-thalassemia (B-thal) Disease Background and Overview

6. Beta-thalassemia (B-thal) Patient Journey

7. Beta-thalassemia (B-thal) Epidemiology and Patient Population

8. Beta-thalassemia (B-thal) Treatment Algorithm, Current Treatment, and Medical Practices

9. Beta-thalassemia (B-thal) Unmet Needs

10. Key Endpoints of Beta-thalassemia (B-thal) Treatment

11. Beta-thalassemia (B-thal) Marketed Products

12. Beta-thalassemia (B-thal) Emerging Therapies

13. Beta-thalassemia (B-thal) Seven Major Market Analysis

14. Attribute Analysis

15. Beta-thalassemia (B-thal) Market Outlook (7 major markets)

16. Beta-thalassemia (B-thal) Access and Reimbursement Overview

17. KOL Views on the Beta-thalassemia (B-thal) Market.

18. Beta-thalassemia (B-thal) Market Drivers

19. Beta-thalassemia (B-thal) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/beta-thalassemia-thal-market

Other Latest Reports By DelveInsight

Idiopathic Thrombocytopenic Purpura Market

DelveInsight’s “Idiopathic Thrombocytopenic Purpura Market” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, Idiopathic Thrombocytopenic Purpura market size, share, trends in the 7MM as well emerging therapies and the key companies operating in the domain.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/